3-氨基-5-(2-甲基苯基)吡唑 | 57860-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氨基-5-(2-甲基苯基)吡唑
• 中文别名: 3-氨基-5-(2-甲基苯基)-1h-吡唑
• 英文名称: 3-Amino-5-(2-methylphenyl)-1H-pyrazole
• 英文别名: 5-(2-methylphenyl)-1H-pyrazol-3-amine
• CAS: 57860-42-1
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD02664272
• 分子量: 173.217
• InChiKey: CKQCUZKXAXOTEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  414.5±33.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-5-(2-methylphenyl)-1h-pyrazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-5-(2-methylphenyl)-1h-pyrazole
CAS number: 57860-42-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11N3
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-5-(2-甲基苯基)吡唑 在 sodium ethanolate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 4.67h， 生成 5-chloro-2-(2-methyl-phenyl)-7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  PYRAZOLO-PYRIMIDINE COMPOUNDS

  摘要：

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。

  公开号：

  US20110294781A1
• 作为产物：
  描述：

  邻甲基苯甲酸甲酯 在 一水合肼 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.0h， 生成 3-氨基-5-(2-甲基苯基)吡唑
  参考文献：
  名称：

  Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives

  摘要：

  A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.07.023

文献信息

• [EN] SYNTHESIS OF PYRAZOLES<br/>[FR] SYNTHÈSE DE PYRAZOLES
  申请人：WYETH CORP

  公开号：WO2009091832A1

  公开（公告）日：2009-07-23

  The present invention provides methods of making HCl salts, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

  本发明提供了制备HCl盐的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病和/或炎症系统等方面。
• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
  申请人：Suzuki Masaki

  公开号：US20150307477A1

  公开（公告）日：2015-10-29

  Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.

  本文描述了利用调节纹状体富集的酪氨酸磷酸酶（STEP）的化合物来治疗疾病的方法。示例疾病包括精神分裂症和认知缺陷。
• Synthesis and enzymic activity of various substituted pyrazolo[1,5-a]-1,3,5-triazines as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors
  作者：Keitaro Senga、Darrell E. O'Brien、Mieka B. Scholten、Thomas Novinson、Jon P. Miller、Roland K. Robins

  DOI：10.1021/jm00345a010

  日期：1982.3

  compound was 8-bromo-4-(diethylamino)-7-phenylpyrazolo[1,3-a]-1,3,5-triazine (25), which was 185 times more potent than theophylline as an inhibitor of PDE isolated from rabbit lung. The stepwise synthesis via ring-closure procedures of requisite pyrazole intermediates, followed by electrophilic substitution in the pyrazole ring and/or nucleophilic substitution in the 1,3,5-triazine moiety, resulted

  已经制备了一系列各种吡唑并[1,5-a] -1,3,5-三嗪作为从牛脑，牛心脏和兔肺中分离的cAMP磷酸二酯酶的抑制剂。发现许多化合物优于茶碱。发现2-乙基-7-苯基吡唑并[1,5-a] -1,3,5-三嗪（35）作为茶黄素对牛脑PDE的抑制剂的功效是茶碱的97倍。8-α-溴2,4,2-二甲基-7-苯基吡唑并[1,5-a] -1,3,5-三嗪（52）显示α肺= 40，而α心脏= 3.0。因此，相对于分离PDE的组织的类型和来源，各种取代基可以增加或减少抑制作用。最具活性的化合物是8-溴-4-（二乙氨基）-7-苯基吡唑并[1,3-a] -1,3,5-三嗪（25），其作为PDE抑制剂的功效比茶碱强185倍从兔肺中分离。通过闭环程序逐步合成必要的吡唑中间体，然后在吡唑环中进行亲电取代和/或在1,3,5-三嗪部分中进行亲核取代，从而生成各种吡唑并[1,5-a] 1表I和II中列出的，3，5-三嗪。构效关系进行了审查。
• [EN] SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF<br/>[FR] PYRAZOLO-PYRIMIDINES SUBSTITUÉES ET LEURS UTILISATIONS
  申请人：VERGE ANALYTICS INC

  公开号：WO2021146192A1

  公开（公告）日：2021-07-22

  The present disclosure provides compounds that are inhibitors of PIKfyve kinases useful for the treatment of neurological diseases treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

  本公开提供了一些抑制PIKfyve激酶的化合物，可用于治疗通过抑制PIKfyve来治疗的神经系统疾病。还提供了含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。